 |
1 Disease |  |
4 Trials |
|
4 Trials |  |
146 News |  |
| 12» |
- ||| cusatuzumab (ARGX-110) / OncoVerity
Enrollment open: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov) - Jul 24, 2024
P2, N=120, Recruiting, Sponsor: OncoVerity, Inc.
Not yet recruiting --> Recruiting
- |||| cusatuzumab (ARGX-110) / OncoVerity
New P2 trial: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov) - Apr 25, 2024
P2, N=120, Not yet recruiting, Sponsor: OncoVerity, Inc.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas. (Pubmed Central) - Nov 28, 2023
The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.
- cusatuzumab (ARGX-110) / OncoVerity
CD70/CD27 Signaling Promotes Expansion of Clonal Plasma Cells in Multiple Myeloma and Is a Promising Therapeutic Target in Advanced Disease (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2365;
Our results indicate that CD70-expressing MM cells have a stem-cell like phenotype and propagate the disease. Targeting CD70 is a promising new therapy especially in advanced disease.
- cusatuzumab (ARGX-110) / OncoVerity
CD70/CD27 SIGNALING PROMOTES THE EXPANSION OF CLONAL PLASMA CELL SUBSETS IN MULTIPLE MYELOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1092;
Our results indicate that especially advanced MM stages express high levels of CD70. In addition, our results indicate that CD70/CD27 cell-autonomous signaling contributes to disease progression and therapy resistance and identifies CD70 as potential target in MM.
- cusatuzumab (ARGX-110) / OncoVerity
VHH-based chimeric antigen receptor T cells against CD70 to eliminate primary and re-challenge renal cell carcinoma tumors in preclinical study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4596;
These CAR constructs include 4 VHH sequences and a human scFv containing VH and VL derived from cusatuzumab... Our results indicate a promising VHH-based CD70 CAR-T cells for RCC therapy, supporting further development for future clinical trial and application.
- IMM01 / ImmuneOnco Biopharma, IMM40H / ImmuneOnco Biopharma, cusatuzumab (ARGX-110) / OncoVerity
Preclinical development of a monoclonal antibody targeting CD70 as cancer immunotherapy (Section 22; Poster Board #17) - Mar 14, 2023 - Abstract #AACR2023AACR_8526;
Interestingly, combination of IMM40H and IMM01 (a SIRP?-IgG1 Fc fusion protein targeting CD47) generated significant therapeutic synergy in models of A498 kidney cancer and Raji lymphoma...IND of IMM40H has been approved in China and US. This antibody is now in a phase 1 study in patients with advanced malignancies expressing CD70.
- | cusatuzumab (ARGX-110) / argenx
Journal: Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Treatment. (Pubmed Central) - Mar 7, 2023
No dose limiting toxicity was observed during the study period. The combination of cusatuzumab and azacitidine is generally well tolerated in Japanese participants and further exploration of this combination is warranted.
- || cusatuzumab (ARGX-110) / argenx
P1/2 data, Journal: Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. (Pubmed Central) - Feb 13, 2023
Thus, cusatuzumab/azacitidine appears generally well tolerated and shows preliminary efficacy in this setting. Investigation of cusatuzumab combined with current standard-of-care therapy, comprising venetoclax and azacitidine, is ongoing.
- || cusatuzumab (ARGX-110) / OncoVerity
Trial completion date, Trial primary completion date, Combination therapy: ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 13, 2023
P1b, N=61, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Investigation of cusatuzumab combined with current standard-of-care therapy, comprising venetoclax and azacitidine, is ongoing. Trial completion date: Jun 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> May 2024
- |||||| cusatuzumab (ARGX-110) / argenx, azacitidine / Generic mfg.
Clinical: Targeting the CD70 in #AML >>> Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy https://t.co/nx9rUbsokr #leusm (Twitter) - Feb 9, 2023
- || cusatuzumab (ARGX-110) / OncoVerity
Trial primary completion date: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Feb 6, 2023
P2, N=103, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> May 2024 Trial primary completion date: Dec 2022 --> Aug 2023
- || cusatuzumab (ARGX-110) / argenx
Trial completion, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Dec 20, 2022
P1/2, N=38, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2022 --> Aug 2023 Active, not recruiting --> Completed
- | cusatuzumab (ARGX-110) / OncoVerity
Trial completion date: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Dec 2, 2022
P2, N=103, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial completion date: Dec 2022 --> Aug 2023
- | cusatuzumab (ARGX-110) / argenx
Trial primary completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Jun 22, 2022
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2022 --> Aug 2023 Trial primary completion date: Apr 2022 --> Oct 2022
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Apr 22, 2022
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Apr 2022 --> Oct 2022 Trial completion date: Apr 2022 --> Oct 2022
- cusatuzumab (ARGX-110) / argenx
TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA () - Apr 20, 2022 - Abstract #ASPHO2022ASPHO_429;
We showed that CD70-CAR NK cells are effective against OS cells in vitro compared to control NK cells. CD70-CAR NK killing does not correlate with an increased level of CD70 expression.
- | cusatuzumab (ARGX-110) / argenx
Journal, IO biomarker: Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. (Pubmed Central) - Mar 11, 2022
Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL. The observed dose-dependent effect on exposure supports the use of 5 mg/kg for future development.
- cusatuzumab (ARGX-110) / argenx
Single-cell spatial transcriptome sequencing characterizes CD70+ immune-resilient nasopharyngeal carcinoma cells as a vital mediator of Treg-induced suppression (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7682;
In this study, we revealed that CD70+ NPC cells were highly resilient to immune surveillance since they were capable of modulating Treg differentiation and activation via the CD70-CD27 interaction to counteract CD8+ T cells. Blocking CD70 has been shown to effectively induce tumor apoptosis by alleviating Treg-mediated suppression.
- || cusatuzumab (ARGX-110) / argenx
Clinical, P1 data, Journal, IO biomarker: An open-label, non-randomized, Phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma. (Pubmed Central) - Feb 23, 2022
Limited activity of cusatuzumab in advanced NPC was observed. Combination therapies of cusatuzumab and other types of therapy should be explored for the improvement of activity in NPC and other CD70-expressing malignancies.
- || cusatuzumab (ARGX-110) / OncoVerity
Trial primary completion date, Combination therapy: ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2022
P1b, N=61, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Combination therapies of cusatuzumab and other types of therapy should be explored for the improvement of activity in NPC and other CD70-expressing malignancies. Trial primary completion date: Nov 2021 --> Dec 2022
- ||||| cusatuzumab (ARGX-110) / argenx
Clinical: Lots of exciting data of triplets being explored in AML w/ Aza/Ven. ELEVATE study- Cusatuzumab/Aza/Ven in newly Dx AML presented by Gail Roboz at #ASH21 w/ interesting data but predictors of response critical. Randomized data needed to see how this fits in Tx armamentarium. (Twitter) - Dec 12, 2021
- CD70-directed CAR-T / Massachusetts General Hospital
Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia (GWCC - B405-B407, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_1779;
Our findings demonstrate that natural-ligand binding domains of CARs targeting CD70 in AML can be effective but require mechanisms to overcome surface cleavage. CD70-targeted CARs comprised of a fusion of truncated CD27 to a CD8 hinge and transmembrane domain have promise in patients with AML, with and without combination with azacitidine.
- Venclexta (venetoclax) / Roche, AbbVie, cusatuzumab (ARGX-110) / argenx
Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study (GWCC - B302-B303, Level 3) - Nov 5, 2021 - Abstract #ASH2021ASH_1737;
Response rates support an additive effect of cusatuzumab to the standard of care with potential for improved clinical outcomes. However, further clinical trials are needed for validation of these initial results.
- || cusatuzumab (ARGX-110) / OncoVerity
Trial completion, Trial completion date, Trial primary completion date: A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment (clinicaltrials.gov) - Oct 8, 2021
P1, N=6, Completed, Sponsor: Janssen Pharmaceutical K.K.
However, further clinical trials are needed for validation of these initial results. Recruiting --> Completed | Trial completion date: Mar 2023 --> Jul 2021 | Trial primary completion date: Dec 2021 --> Jul 2021
- | cusatuzumab (ARGX-110) / argenx
Trial primary completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Sep 1, 2021
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed | Trial completion date: Mar 2023 --> Jul 2021 | Trial primary completion date: Dec 2021 --> Jul 2021 Trial primary completion date: Jul 2021 --> Apr 2022
- || cusatuzumab (ARGX-110) / OncoVerity
Trial primary completion date, Combination therapy: ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 1, 2021
P1b, N=60, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2021 --> Apr 2022 Trial primary completion date: Jun 2021 --> Nov 2021
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jun 2021 --> Nov 2021 Trial completion date: Jul 2021 --> Apr 2022
- || cusatuzumab (ARGX-110) / OncoVerity
Trial completion date, Trial primary completion date: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Aug 18, 2021
P2, N=103, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2021 --> Apr 2022 Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Mar 2022 --> Dec 2022
- | cusatuzumab (ARGX-110) / argenx
Journal: The CD70 Antibody Cusatuzumab Shows Promise in Acute Myeloid Leukemia. (Pubmed Central) - Aug 13, 2021
Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Mar 2022 --> Dec 2022 Cusatuzumab synergized with a hypomethylating agent in older patients with acute myeloid leukemia.
- || azacitidine / Generic mfg.
Clinical, Review, Journal: An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. (Pubmed Central) - Aug 4, 2021
Gemtuzumab ozogamicin, a CD33 directed antibody-drug conjugate, has provided the proof of concept for the potential efficacy of monoclonal antibody-based therapies in AML...The first-in-class anti-CD47 antibody magrolimab and anti-CD70 antibody cusatuzumab in combination with hypomethylating agent (HMA) azacitidine, in newly diagnosed AML, and flotetuzumab, a bispecific DART® (dual-affinity retargeting) antibody to CD3ε and CD123 as salvage option in relapsed/refractory AML appear promising...Ongoing research will define the choice of an appropriate complementary therapeutic agent in antibody-based combination therapy, and whether one or more than one antigen should be simultaneously targeted. Further studies will likely refine the role of antibody-based therapy in post hematopoietic cell transplant setting.
- || cusatuzumab (ARGX-110) / argenx, J&J
$ARGX argenx to regain global rights to cusatuzumab https://t.co/c1IyH7cj7n (Twitter) - Jun 6, 2021
- | cusatuzumab (ARGX-110) / argenx
Enrollment change, Trial withdrawal, Combination therapy: A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Jun 4, 2021
P2, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
Further studies will likely refine the role of antibody-based therapy in post hematopoietic cell transplant setting. N=170 --> 0 | Not yet recruiting --> Withdrawn
- || cusatuzumab (ARGX-110) / OncoVerity
Enrollment closed, Combination therapy: ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) - May 20, 2021
P1b, N=60, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=170 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Combination therapy: A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Apr 23, 2021
P2, N=170, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial completion date: Jul 2024 --> Jan 2025
- || cusatuzumab (ARGX-110) / OncoVerity
Trial completion date, Trial primary completion date: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Apr 22, 2021
P2, N=103, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2024 --> Jan 2025 Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Feb 2021 --> Mar 2022
- | cusatuzumab (ARGX-110) / argenx
Trial primary completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Feb 2, 2021
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Feb 2021 --> Mar 2022 Trial primary completion date: Dec 2020 --> Jul 2021
- |||| cusatuzumab (ARGX-110) / argenx, J&J
Some news about $ARGX CD70 antibody cusatuzumab in #AML: after 92% ORR & 83% CR/CRi was reported at #ASH18 (based on n=12), announced today that CR/CRi down to 40% (21/52). A reminder that early HMA combo data in MDS/AML can be misleading. @andrewbrunner https://t.co/Qwx9nxRyMI (Twitter) - Jan 8, 2021
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Dec 4, 2020
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2020 --> Jul 2021 Trial completion date: Dec 2020 --> Jul 2021
- || cusatuzumab (ARGX-110) / argenx
Clinical, Journal, IO biomarker: Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. (Pubmed Central) - Nov 6, 2020
P1/2
No dose-limiting toxicities were reported and the maximum tolerated dose of cusatuzumab was not reached. Importantly, cusatuzumab treatment substantially reduced LSCs and triggered gene signatures related to myeloid differentiation and apoptosis.
- | cusatuzumab (ARGX-110) / OncoVerity
Enrollment closed: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Sep 13, 2020
P2, N=103, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Importantly, cusatuzumab treatment substantially reduced LSCs and triggered gene signatures related to myeloid differentiation and apoptosis. Recruiting --> Active, not recruiting
- | cusatuzumab (ARGX-110) / argenx
Trial initiation date, Combination therapy: A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Sep 11, 2020
P2, N=150, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Initiation date: Aug 2020 --> Mar 2021
- | Venclexta (venetoclax) / Roche, AbbVie, cusatuzumab (ARGX-110) / argenx, J&J
you mean cusatuzumab setback vs venetoclax or smthg relating to efgatigimod? (Twitter) - Aug 19, 2020
- ||| cusatuzumab (ARGX-110) / OncoVerity
Enrollment change: CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov) - Aug 13, 2020
P2, N=103, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Aug 2020 --> Mar 2021 N=150 --> 103
- ||||| cusatuzumab (ARGX-110) / argenx, J&J
Clinical, Combination therapy: Open #clinicaltrial #2019-0989 Cusatuzumab in Combination With Background Therapy for the Treatment of Participants w/ #AML (ELEVATE) | PI: @DrHKantarjian of @MDAndersonNews #Leukemia | NCT04150887 | https://t.co/UK8aVnI0F6 | #endcancer #leusm (Twitter) - Jul 23, 2020
P1b
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Combination therapy: A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Jul 21, 2020
P2, N=150, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
N=150 --> 103 Trial completion date: Jul 2022 --> Jul 2024
- ||| cusatuzumab (ARGX-110) / OncoVerity
Trial completion, Trial completion date, Metastases: A Study of ARGX-110 in Participants With Advanced Malignancies (clinicaltrials.gov) - Jul 21, 2020
P1/2, N=99, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2022 --> Jul 2024 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020
- | cusatuzumab (ARGX-110) / argenx
Trial completion date, Trial primary completion date, Combination therapy: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (clinicaltrials.gov) - Jul 17, 2020
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020 Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Dec 2020
- || cusatuzumab (ARGX-110) / OncoVerity
Enrollment change, Combination therapy: ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 16, 2020
P1b, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Dec 2020 N=60 --> 80
- | cusatuzumab (ARGX-110) / argenx, J&J
Journal: The CD70 Antibody Cusatuzumab Shows Promise in Acute Myeloid Leukemia. (Pubmed Central) - Jul 12, 2020
N=60 --> 80 Cusatuzumab synergized with a hypomethylating agent in older patients with acute myeloid leukemia.